MerlinS13 phosphorylation regulates meningioma Wnt signaling and magnetic resonance imaging features

Charlotte D Eaton,Lauro Avalos,S John Liu,Zhenhong Chen,Naomi Zakimi,Tim Casey-Clyde,Paola Bisignano,Calixto-Hope G Lucas,Erica Stevenson,Abrar Choudhury,Harish N Vasudevan,Stephen T Magill,Jacob S Young,Nevan J Krogan,Javier E Villanueva-Meyer,Danielle L Swaney,David R Raleigh

DOI: https://doi.org/10.1038/s41467-024-52284-8

2024-09-09

Abstract:Meningiomas are associated with inactivation of NF2/Merlin, but approximately one-third of meningiomas with favorable clinical outcomes retain Merlin expression. Biochemical mechanisms underlying Merlin-intact meningioma growth are incompletely understood, and non-invasive biomarkers that may be used to guide treatment de-escalation or imaging surveillance are lacking. Here, we use single-cell RNA sequencing, proximity-labeling proteomic mass spectrometry, mechanistic and functional approaches, and magnetic resonance imaging (MRI) across meningioma xenografts and patients to define biochemical mechanisms and an imaging biomarker that underlie Merlin-intact meningiomas. We find Merlin serine 13 (S13) dephosphorylation drives meningioma Wnt signaling and tumor growth by attenuating inhibitory interactions with β-catenin and activating the Wnt pathway. MRI analyses show Merlin-intact meningiomas with S13 phosphorylation and favorable clinical outcomes are associated with high apparent diffusion coefficient (ADC). These results define mechanisms underlying a potential imaging biomarker that could be used to guide treatment de-escalation or imaging surveillance for patients with Merlin-intact meningiomas.